Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside.
about
Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine bindingCrystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivityStructural insight into substrate specificity of phosphodiesterase 10The Molecular Basis for Different Recognition of Substrates by Phosphodiesterase Families 4 and 10Conformational Variations of Both Phosphodiesterase-5 and Inhibitors Provide the Structural Basis for the Physiological Effects of Vardenafil and SildenafilAn insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studiesMultiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7.Effects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options.Recent advances in management of bladder overactivity.Prospective pharmacologic therapies for the overactive bladderSelective inhibition of phosphodiesterase 1 relaxes urinary bladder smooth muscle: role for ryanodine receptor-mediated BK channel activation.Constitutively active phosphodiesterase activity regulates urinary bladder smooth muscle function: critical role of KCa1.1 channel.Lower urinary-tract symptoms and testosterone in elderly menTadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action.Phosphodiesterase inhibitors in clinical urology.The role of phosphodiesterases in bladder pathophysiology.Chronic bladder ischemia and oxidative stress: new pharmacotherapeutic targets for lower urinary tract symptoms.Impact of postoperative phosphodiesterase type 5 inhibitor treatment on lower urinary tract symptoms after robot-assisted radical prostatectomy: a longitudinal study.PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis.Expression and distribution of key enzymes of the cyclic GMP signaling in the human clitoris: relation to phosphodiesterase type 5 (PDE5).Vardenafil-induced relaxation and cyclic nucleotide levels in normal and obstructed rat urinary bladder.An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidaemic rat.Effect of sildenafil citrate in testosterone induced benign prostate hyperplasia rat model.Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects.
P2860
Q24562006-FECB21FC-D1D5-46B2-BEB2-9741632C258FQ27642760-3AC2FF8C-9F90-4EF1-BA02-4A448222135CQ27644254-F0DE92C5-DAA7-4311-AC00-C6CB810980FAQ27646209-1BC163B5-0F25-4F97-AF0C-FB5FD7147768Q27648887-BB48CF69-9A1D-4BE4-A952-ED2F41AE2239Q27650091-BFE05895-DE60-4B8C-B150-D9314E77D74DQ33341310-32E8ABAB-A8C0-440C-BA08-7971002130CEQ34114694-AD1F9EDF-1E48-4C62-826C-534A3D745160Q34167658-0F9E277F-D727-4406-AD2D-816D034229BAQ35076367-391808EB-7849-498F-BB13-02099B20A855Q36382456-31E479EC-4F65-4FB3-8BB0-F6BA2BF92373Q36455850-E753A636-F012-48B1-B15C-F9E0EF667008Q36839032-A30E4F89-C213-46E9-9D24-FB23E4107A54Q37833959-9D981DC9-35E1-47D7-9274-6A6BB078B46AQ38063330-8C5BF7EE-9DBB-4ED3-A0FC-6C844FDE45D8Q38105149-83403724-D57A-40A7-9C1D-E185CD29E853Q38106628-CF055475-297B-4803-BB7B-4678A8FF79D3Q38262087-5215F923-2604-44E4-AC60-E30DE9A32006Q39190285-14FC19EA-8B2A-49EF-8319-E80970A358D3Q42325938-EAEE4502-CCEC-4C3A-A8E3-6FD0F73597E3Q42490401-D031D113-15AB-44FF-A1A5-1508EE187F9EQ43289038-C4E94920-CAE4-4746-AE58-724F3DE510A9Q46560411-9DEAA6F8-023F-41C6-BEE7-C78C8F4A3675Q46788913-F251D86E-D776-46A2-AF95-611544D5ED5AQ51809623-485214E2-629A-4199-BE74-34168FEFA9B5
P2860
Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Phosphodiesterase 1 inhibition ...... nction: from bench to bedside.
@ast
Phosphodiesterase 1 inhibition ...... nction: from bench to bedside.
@en
Phosphodiesterase 1 inhibition ...... nction: from bench to bedside.
@nl
type
label
Phosphodiesterase 1 inhibition ...... nction: from bench to bedside.
@ast
Phosphodiesterase 1 inhibition ...... nction: from bench to bedside.
@en
Phosphodiesterase 1 inhibition ...... nction: from bench to bedside.
@nl
prefLabel
Phosphodiesterase 1 inhibition ...... nction: from bench to bedside.
@ast
Phosphodiesterase 1 inhibition ...... nction: from bench to bedside.
@en
Phosphodiesterase 1 inhibition ...... nction: from bench to bedside.
@nl
P2093
P356
P1476
Phosphodiesterase 1 inhibition ...... nction: from bench to bedside.
@en
P2093
Schultheiss D
P2888
P304
P356
10.1007/S003450100221
P577
2001-11-01T00:00:00Z
P6179
1013437175